Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
AMES, Iowa, May 08, 2017 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the following upcoming investor conferences:
- Bank of America Merrill Lynch 2017 Health Care Conference on May 18 in Las Vegas, NV
- Jefferies 2017 Global Healthcare Conference on June 8 at 11:30am ET in New York City
A live webcast of the Jefferies conference presentation will be on the Company's website at www.newlinkgenetics.com in the "Investors & Media" section under "Events and Presentations."
About NewLink Genetics Corporation
NewLink Genetics is a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' product candidates are designed to harness multiple components of the immune system to combat cancer. For more information, please visit http://www.newlinkgenetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include any statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink Genetics makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics' Annual Report on Form 10-K for the year ended December 31, 2016 and other reports filed with the U.S. Securities and Exchange Commission (SEC). The forward-looking statements in this press release represent NewLink Genetics' views as of the date of this press release. NewLink Genetics anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.
Investor Relations Contact: Lisa Miller Director of Investor Relations NewLink Genetics (515) 598-2555 [email protected] Investor and Media Contacts: Beth Kurth, VP LaVoieHealthScience (617) 374-8800, ext. 106 [email protected] Sharon Correia, VP LaVoieHealthScience (617) 374-8800, ext. 105 [email protected]
